Replies to post #27 on Alexion Pharmaceuticals, Inc. (ALXN)

[stocktrader001]

UBS AG (UBS) Analysts Raise Price Target on Alexion Pharmaceuticals, Inc. (ALXN) Shares to $93

Equities research analysts at UBS AG (NYSE: UBS) boosted their price target on shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) from $85.00 to $93.00 in a research note to investors on Friday. The analysts currently have a “neutral” rating on the stock.

Separately, analysts at Collins Stewart raised their price target on shares of Alexion Pharmaceuticals, Inc. from $80.00 to $99.00 in a research note to investors on Friday. They now have a “buy” rating on the stock.

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. for the production of Soliris.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) traded down 0.24% during mid-day trading on Monday, hitting $89.83. Alexion Pharmaceuticals, Inc. has a 52 week low of $45.18 and a 52 week high of $90.29. The stock’s 50-day moving average is $84.00 and its 200-day moving average is $70.58. On average, analysts predict that Alexion Pharmaceuticals, Inc. will post $0.58 EPS next quarter. The company has a market cap of $8.129 billion and a price-to-earnings ratio of 27.02.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts’ upgrades, analysts’ downgrades and analysts’ price target changes for each day. Click Here to register.

http://www.americanbankingnews.com/2011/02/14/ubs-ag-ubs-analysts-raise-price-target-on-alexion-pharmaceuticals-inc-alxn-shares-to-93-00/